Financial reports
Current reports
6-K
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
13 May 24
6-K
Belite Bio Announces $25 Million Registered Direct Offering
25 Apr 24
6-K
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
22 Mar 24
6-K
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
11 Mar 24
6-K
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
11 Mar 24
6-K
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
13 Nov 23
6-K
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting
6 Nov 23
6-K
Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results
9 Aug 23
6-K
Belite Bio Completes Enrollment in Pivotal Global Phase 3
24 Jul 23
6-K
Current report (foreign)
16 Jun 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
29 Apr 24
S-8
Registration of securities for employees
19 Sep 23
424B5
Prospectus supplement for primary offering
16 Jun 23
424B5
Prospectus supplement for primary offering
1 Jun 23
424B5
Prospectus supplement for primary offering
30 May 23
F-3
Shelf registration (foreign)
22 May 23
F-3
Shelf registration (foreign)
1 May 23
S-8
Registration of securities for employees
8 Jul 22
424B4
Prospectus supplement with pricing info
29 Apr 22
F-1/A
Registration statement (foreign) (amended)
27 Apr 22
Proxies
No filings
Other
EFFECT
Notice of effectiveness
31 May 23
CORRESP
Correspondence with SEC
25 May 23
UPLOAD
Letter from SEC
25 May 23
EFFECT
Notice of effectiveness
10 May 23
CORRESP
Correspondence with SEC
5 May 23
UPLOAD
Letter from SEC
5 May 23
EFFECT
Notice of effectiveness
29 Apr 22
EFFECT
Notice of effectiveness
28 Apr 22
SEC STAFF
SEC staff action: Order
28 Apr 22
CERT
Certification of approval for exchange listing
25 Apr 22
Ownership
144
Notice of proposed sale of securities
4 Jun 24
144
Notice of proposed sale of securities
30 May 24
144
Notice of proposed sale of securities
30 May 24
144
Notice of proposed sale of securities
17 May 24
144
Notice of proposed sale of securities
16 May 24
144
Notice of proposed sale of securities
22 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
SC 13G
Lin Yu-Hsin
12 Feb 24
SC 13G
Lin Bioscience International Ltd.
12 Feb 24
144
Notice of proposed sale of securities
28 Dec 23